Combined autophagy and proteasome inhibition: a phase 1 trial
of hydroxychloroquine and bortezomib in patients with relapsed / refractory myeloma.
Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis
of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
Whereas, a phase I / II trial
of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme led to no significant improvement in overall survival, which could be due to inconsistent autophagy inhibition in patients treated with this regimen [29].
A phase I / II trial
of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Not exact matches
The first group was given the antibiotic doxycycline for 12 weeks, the second group was given a combination
of the antibiotics clarithromycin and
hydroxychloroquine, and the third group was given a placebo.
Lead researcher Dr Sarah Kingsbury, from the University
of Leeds and NIHR Leeds Biomedical Research Centre at Chapel Allerton Hospital, said: «There is some scientific basis as to why
hydroxychloroquine could be an effective drug agent.
The study, led by Didier Raoult,
of Aix - Marseille University, Marseille, France, followed 48 patients who were being treated long - term with doxycycline and
hydroxychloroquine for Q fever, and 34 control subjects.
The arms hold it in place while
hydroxychloroquine, a malaria medication also shown to calm immune activation, is delivered and slowly absorbed by the walls
of the vaginal tract.
The inspection
of several databases led to the identification
of structural similarity between such lead and numerous quinoline or acridine derivatives, such as chloroquine,
hydroxychloroquine and quinacrine.
Hydroxychloroquine is an antimalarial drug which is relatively safe and well - tolerated agent for the treatment
of rheumatoid arthritis.
It is also given in conjunction with methotrexate and
hydroxychloroquine as part
of a regimen
of «triple therapy» which has been shown to provide benefits to patients who have had inadequate responses to methotrexate alone.
In preclinical trials, the effect
of chloroquine and
hydroxychloroquine on tumorigenesis has been extensively investigated in mouse cancer models, including genetic and xenograft models (summarized in Table 2).